Galectin Therapeutics
GALT · NASDAQ
$3.43−$0.06 (−1.72%)TodayMarket closed ·
Prev close $3.49
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 21.6% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0918 | -$0.14 | −52.5% |
| Q1 FY26 | -$0.0612 | -$0.08 | −30.7% |
| Q4 FY25 | -$0.102 | -$0.08 | +21.6% |
| Q3 FY25 | -$0.1122 | -$0.13 | −15.9% |
| Q2 FY25 | -$0.1632 | -$0.12 | +26.5% |
| Q1 FY25 | -$0.204 | -$0.15 | +26.5% |
| Q4 FY24 | -$0.1632 | -$0.19 | −16.4% |
| Q3 FY24 | -$0.204 | -$0.18 | +11.8% |
Earnings calls
- Special Call - Galectin Therapeutics Inc.
- Special Call - Galectin Therapeutics Inc.
- Shareholder/Analyst Call - Galectin Therapeutics Inc.
- Shareholder/Analyst Call - Galectin Therapeutics Inc.
- Special Call - Galectin Therapeutics Inc.
- Shareholder/Analyst Call - Galectin Therapeutics Inc.
- Galectin Therapeutics' (GALT) Management Discusses Phase 2b NASH-CX Trial Results Conference Call
- Earnings call Q4 2016
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.